Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective studyJesús García-Donás, Cristina Rodríguez‐Antona, Albert Font et al.|The Lancet Oncology|2011Cited by 221
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trialRafael Rosell, Rolf A. Stahel, Urania Dafni et al.|The Lancet Respiratory Medicine|2017Cited by 184
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinomaJesús García-Donás, Cristina Rodríguez‐Antona, Luis J. Leandro‐García et al.|Annals of Oncology|2013Cited by 74
PTEN expression and mutations in <i>TSC1</i>, <i>TSC2</i> and <i>MTOR</i> are associated with response to rapalogs in patients with renal cell carcinomaJuan María Roldán‐Romero, Benoit Beuselinck, María Santos et al.|International Journal of Cancer|2019Cited by 29
Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI).Sumanta K. Pal, Sun Young Rha, Javier Puente et al.|Journal of Clinical Oncology|2021Cited by 11